An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the activity of ZD1839 in patients with malignant mesothelioma by estimating the objective response rate (CR and PR) at trial closure
Proportion of patients responding at trial closure, ITT population
No
Christopher Lee, MD
Principal Investigator
Fraser Valley Cancer Centre Surrey Memorial Hospital, Surrey BC, Canada
Canada: Health Canada
1839IL/0094
NCT00787410
September 2003
April 2008
Name | Location |
---|